Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin

By Kelly M, O'Connor R, Townsend L, et al
Published August 27, 2020

Key Takeaways

In this study, the clinical outcomes and adverse drug events were explored in patients hospitalized with COVID‐19 treated with off‐label hydroxychloroquine (HCQ) and azithromycin (Az). Researchers conducted a retrospective analysis of hospitalized patients who had a positive polymerase chain reaction test for SARS‐CoV‐2 and received HCQ plus Az or no targeted therapy. The primary outcome included clinical improvement on day 7 defined as either hospital discharge or improvement of 2 points on a 6‐category ordinal scale. The mortality at day 28, intensive care admission, the requirement for mechanical ventilation and incidence of adverse events were considered as secondary outcomes. They examined data from a total of 134 patients; 82 patients received HCQ/Az and 52 patients received no targeted therapy.  It was shown that the administration of these repurposed drugs did not result in clinical improvement and was associated with a significant increase in toxicity, although patients who received HCQ/Az were more severely ill. This descriptive study indicates the utility of monitoring all repurposed agents for adverse events.

Read the full article on British Journal of Clinical Pharmacology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter